Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis

— Triveni Bio enters the clinic with TRIV-509 and plans to initiate two additional patient studies in the second half of 2025 — — Scientific presentations elucidate the importance of KLK5/7 in AD disease pathology and support advancement of second-generation bispecific antibody, TRIV-573, in IND-enabling studies — WATERTOWN, MA – May 21, 2025 – Triveni Bio, Inc., a biotechnology company […] The post Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis appear